1. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial 
Amit Arjyal, MD, Prof Buddha Basnyat, MD, Ho Thi Nhan, PhD, Samir Koirala, MD, Abhishek Giri, MD, Niva Joshi, BSc, Mila Shakya, MD, Kamal Raj Pathak, MD, Saruna Pathak Mahat, MD, Shanti Pradhan Prajapati, MD, Nabin Adhikari, MA, Rajkumar Thapa, MPharm, Laura Merson, BSc, Damodar Gajurel, MD, Kamal Lamsal, MD, Dinesh Lamsal, MD, Prof Bharat Kumar Yadav, MD, Ganesh Shah, MD, Poojan Shrestha, BDS, Sabina Dongol, PhD, Abhilasha Karkey, PhD, Corinne N Thompson, MSc, Nga Tran Vu Thieu, MSc, Duy Pham Thanh, MSc, Stephen Baker, PhD, Prof Guy E Thwaites, MD, Marcel Wolbers, PhD, Christiane Dolecek, MD 
The Lancet Infectious Diseases 
Volume 16, Issue 5, Pages (May 2016)
DOI: /S (15)
Copyright © 2016 Arjyal et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
Salmonella enterica Typhi or Salmonella enterica Paratyphi A were isolated from the blood of patients with culture-confirmed enteric fever.
The Lancet Infectious Diseases  , DOI: ( /S (15) )
Copyright © 2016 Arjyal et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Time to treatment failure and fever clearance time
Time to treatment failure shown in the (A) modified intention to treat, (B) culture-confirmed, and (C) culture-negative populations. Fever clearance times shown in the (D) modified intention to treat, (E) culture-confirmed, and (F) culture-negative populations. Fever clearance times were interval-censored; because numbers at risk are not well defined in this setting they are not shown for graphs D, E, or F. HR=hazard ratio. AF=acceleration factor.
The Lancet Infectious Diseases  , DOI: ( /S (15) )
Copyright © 2016 Arjyal et al. Open Access article distributed under the terms of CC BY Terms and Conditions